Cutting the cost of drug development?

被引:117
作者
Rawlins, MD [1 ]
机构
[1] Newcastle Univ, Sch Med, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
基金
美国国家卫生研究院; 英国医学研究理事会; 英国惠康基金;
关键词
D O I
10.1038/nrd1347
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The cost of drug development has risen markedly in the past 30 years, with studies now reporting values exceeding US $800 million. As these spiralling costs threaten to make the development of new drugs increasingly unaffordable for both developing companies and consumers, it is clear that efforts should be made to address this problem. All aspects of the drug discovery and development process should be examined for potential cost savings, but I focus here in particular on the current regulatory requirements.
引用
收藏
页码:360 / 364A
页数:5
相关论文
共 20 条
[1]  
Altman DG, 1999, BRIT MED J, V318, P1209
[2]  
[Anonymous], 2001, SMALL CLIN TRIALS IS
[3]  
[Anonymous], 2003, PHARM ETH ISS
[4]  
*BOST CONS GROUP, 2001, REV R D GEN GEN TRAN
[5]   DESIGN CONSIDERATIONS FOR AIDS TRIALS [J].
BYAR, DP ;
SCHOENFELD, DA ;
GREEN, SB ;
AMATO, DA ;
DAVIS, R ;
DEGRUTTOLA, V ;
FINKELSTEIN, DM ;
GATSONIS, C ;
GELBER, RD ;
LAGAKOS, S ;
LEFKOPOULOU, M ;
TSIATIS, AA ;
ZELEN, M ;
PETO, J ;
FREEDMAN, LS ;
GAIL, M ;
SIMON, R ;
ELLENBERG, SS ;
ANDERSON, JR ;
COLLINS, R ;
PETO, R ;
PETO, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1343-1348
[6]   Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].
Concato, J ;
Shah, N ;
Horwitz, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892
[7]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[8]   RETURNS TO RESEARCH-AND-DEVELOPMENT ON NEW DRUG INTRODUCTIONS IN THE 1980S [J].
GRABOWSKI, HG ;
VERNON, JM .
JOURNAL OF HEALTH ECONOMICS, 1994, 13 (04) :383-406
[9]  
HARRIS G, 2003, NY TIMES 1005
[10]   New active substances authorized in the United Kingdom between 1972 and 1994 [J].
Jefferys, DB ;
Leakey, D ;
Lewis, JA ;
Payne, S ;
Rawlins, MD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (02) :151-156